Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ISB 1342 |
Synonyms | |
Therapy Description |
ISB 1342 (GBR 1342) is a bispecific antibody that binds CD3 and CD38, potentially resulting in cytotoxic activity against CD38-positive cells (Journal of Clinical Oncology 2018 36:15_suppl, TPS3132). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ISB 1342 | ISB-1342|ISB1342|GBR 1342|GBR1342|GBR-1342 | CD3 Antibody 99 CD38 Antibody 20 | ISB 1342 (GBR 1342) is a bispecific antibody that binds CD3 and CD38, potentially resulting in cytotoxic activity against CD38-positive cells (Journal of Clinical Oncology 2018 36:15_suppl, TPS3132). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03309111 | Phase I | ISB 1342 | Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma | Completed | USA | FRA | 0 |